Tempus rises premarket on Merck, Moderna collaboration news
Tempus shares are up 13% premarket after market talk pointed to expanded strategic collaboration with Merck and an ongoing expanded partnership with Moderna through Tempus AI data platforms.
TEM shares +13% premarket - likely up on MRNA MRK news today primarily as a Precision Oncology/AI Diagnostics and data play.
Note Tempus has an expanded multi-year strategic collaboration with Merck focused on AI-driven Precision Medicine, biomarker Discovery, resistance mechanisms, and rational combinations using Tempus’s de-identified multimodal data + Lens platform/Workspaces.
Also, Moderna utilizes Tempus AI’s genetic and multimodal data platform primarily through an ongoing, expanded partnership with Tempus’ clinical partner, Personalis.